MedTrace Logo

Preference Tiotropium Respimat Study in COPD

NCT01810692 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2015-03-26

Study results available
· View outcomes & findings →

Summary

In COPD the patient's ability to use inhalers correctly and their preference for the inhaler are both important factors in selecting an appropriate treatment for COPD. This is a cross-sectional study where satisfaction, preference and handling of two different devices such as Respimat and Breezhaler will be evaluated by using the validated PASAPQ in COPD patients

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Group1:Spiriva® Respimat®

COPD patients using Respimat®

DEVICE

Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®

COPD patients using Breezhaler®®

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01810692 on ClinicalTrials.gov